Press releases about „lvef“ sorted by

Date of release

• Date of release
• Relevance

Search: press release lvef

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

• 2020-05-29
• Medical Technology
• DAIICHI SANKYO EUROPE GmbH

Results from the phase 2 DESTINY-CRC01  trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERT­U®     (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.... go to the press release

---

Search: press release lvef

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

• 2020-05-29
• Medical Technology
• DAIICHI SANKYO EUROPE GmbH

First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy Breakth­rough Therapy Designation recently granted in the U.S. for ENHERTU in this setting Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01... go to the press release

---

Search: press release lvef

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

• 2020-05-29
• Medical Technology
• DAIICHI SANKYO EUROPE GmbH

9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthroug­h Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab... go to the press release

---

Search: press release lvef

BIOTRONIK Announces First Enrollments in the BIO|GUARD-MI Study

• 2015-08-07
• Medical Technology
• BIOTRONIK

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early detection of cardiac arrhythmias offered by BioMonitor, and subsequent treatments, reduce the likelihood of major adverse cardiovascular events (MACE*). The study will,... go to the press release

---

Search: press release lvef

BIOTRONIK gibt Aufnahme der ersten Patienten in die BIO|GUARD-MI-Studie bekannt

• 2015-08-07
• Medical Technology
• BIOTRONIK

BIOTRONIK, ein führender Hersteller kardiovaskulärer Medizintechnik, hat heute die Aufnahme der ersten Patienten in die Studie BIO|GUARD-MI bekanntgegeben. Im Rahmen der Studie wird geprüft, ob die Früherkennung von Herzrhythmus-störungen durch den BioMonitor mit BIOTRONIK Home Monitoring® das Auftreten schwerwiegender kardiovaskulärer Komplikationen... go to the press release

---

Search: press release lvef

BIOTRONIK Announces Start of First Study to Assess Relevance of Defibrillator Back-Up after CRT-D Replacement

• 2015-08-05
• Research / Development
• BIOTRONIK

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to assess the CONTINUation of Existing risk of ventricular arrhythmias after CRT-D replacement). BioCONTINUE is the first study to investigate the relevance of defibrillator... go to the press release

---

Search: press release lvef

Early Detection, Early Intervention at this Year's EMB Conference

• 2014-02-10
• Medical Technology
• BIOTRONIK

Experts in cardiology and electrophysiology met at this year's 8th annual EMB (Expert Meeting Berlin) Conference[1] to discuss critical issues affecting their fields. Among the topics addressed were: How can remote monitoring and early detection help improve therapy for heart failure patients? When is the right time for catheter ablation when treating... go to the press release

---

Search: press release lvef

More Effective Risk-Stratification for ICD Interventions Needed: BIOTRONIK PARCADIA Study Aims to Address Open Clinical Questions

• 2012-08-31
• Medical Technology
• BIOTRONIK

MADIT-II Showed that 75% of Patients Did Not Receive Shock Therapy -- Did They Really Require an ICD Implant? 2012 - BIOTRONIK, a leading manufacturer of innovative medical technology, today announced the start of the prospective multicenter PARCADIA study. The study aims to identify risk factors that can help predict appropriate ICD (implantable... go to the press release

---

Search: press release lvef

Effektivere Risikostratifikation bei ICD-Interventionen erforderlich: BIOTRONIK PARCADIA Studie untersucht welche Patienten den größten Nutzen haben

• 2012-08-31
• Medical Technology
• BIOTRONIK

MADIT-II-Studie hat gezeigt, dass 75% der ICD-Patienten keine Schocktherapie erhielten - war die Implantation angemessen? BIOTR­ONIK, ein führender Hersteller innovativer Medizintechnik, verkündete heute den Start der prospektiven multizentrischen PARCADIA Studie. Ziel der Studie ist die Identifikation von Risikofaktoren zur Vorhersage des Nutzens... go to the press release

---

Search: press release lvef

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology

• 2012-01-24
• Company-internal
• Cytori Therapeutics, Inc.

Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College... go to the press release